IRIDEX Co. (NASDAQ:IRIX - Get Free Report) Director Beverly A. Huss purchased 25,900 shares of the stock in a transaction on Wednesday, April 23rd. The stock was bought at an average cost of $1.22 per share, for a total transaction of $31,598.00. Following the completion of the acquisition, the director now owns 92,639 shares in the company, valued at approximately $113,019.58. This trade represents a 38.81 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
IRIDEX Stock Down 4.9 %
IRIX opened at $1.16 on Friday. The stock has a fifty day moving average of $1.10 and a 200-day moving average of $1.46. The company has a market capitalization of $19.48 million, a P/E ratio of -1.73 and a beta of 0.74. IRIDEX Co. has a fifty-two week low of $0.78 and a fifty-two week high of $3.25. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.85 and a current ratio of 1.54.
IRIDEX (NASDAQ:IRIX - Get Free Report) last posted its quarterly earnings data on Thursday, March 27th. The medical equipment provider reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.05). IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. The firm had revenue of $12.70 million during the quarter, compared to the consensus estimate of $12.80 million.
Wall Street Analysts Forecast Growth
Separately, StockNews.com assumed coverage on IRIDEX in a research report on Friday, April 18th. They issued a "hold" rating on the stock.
View Our Latest Research Report on IRIX
About IRIDEX
(
Get Free Report)
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
